Anti-nerve growth factor monoclonal antibodies – Librela
spotlight topic:
Librela
Published 10 September 2025
- Veterinary Medicines Directorate (2024) Summary of Product Characteristics: Librela 10 mg solution for injection for dogs [DEFRA] [online]. Available from: https://www.vmd.defra.gov.uk/ProductInformationDatabase/files/SPC_Documents/SPC_2310364.PD [Accessed 8 September 2025]
- Veterinary Medicines Directorate (2025) Post Authorisation Assessments: Librela 10 mg solution for injection for dogs [DEFRA] [online]. Available from: https://www.vmd.defra.gov.uk/ProductInformationDatabase/files/PAA_Documents/PAA_2214138.PDF [Accessed 8 September 2025]
- Veterinary Medicines. Librela 10 mg – Solution for injection [European Medicines Agency] [online]. Available from: https://medicines.health.europa.eu/veterinary/en/600000001761 [Accessed 8 September 2025]
- Librela: EPAR – Medicine overview [European Medicines Agency] [online]. Available from: https://medicineshttps://www.ema.europa.eu/en/medicines/veterinary/EPAR/librela [Accessed 8 September 2025]
- Veterinary Medicines Directorate (2025) VMD response to concerns raised following media reports of serious adverse events in dogs administered Librela [DEFRA] [online]. https://www.gov.uk/government/news/librela-solution-for-injection-in-dogs [Accessed 8 September 2025]
- U.S. Food & Drug Administration (2024) FDA Standard adverse event review: Librela [FDA] [online] Available: https://www.fda.gov/media/184483/ [Accessed 8 September 2025]
Claiming CPD for reading inFOCUS articles
Reading and reflecting on articles can count towards your CPD, and we have a template to help you with the process.
Online full-text available to Library members
A range of library membership packages is available and MRCVS vets and RVNs can join the library for a heavily subsidised, annual fee.
Leave a Reply
Want to join the discussion?Feel free to contribute!